Cera Nieto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cera Nieto has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Jimeno
UC Health Cancer Center, Aurora, Colorado
35 shared publications - J. Jason Morton
Division of Medical Oncology, Department of Medicine, University of Colorado Denver School of Medicine (UCDSOM), Aurora, Colorado
34 shared publications - Phuong N. Le
Division of Medical Oncology, Department of Medicine, University of Colorado Denver School of Medicine (UCDSOM), Aurora, Colorado
34 shared publications - Stephen B. Keysar
Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado
34 shared publications - Alice N. Weaver
Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado
30 shared publications - Carissa M. Thomas
Department of Otolaryngology University of Alabama at Birmingham Birmingham Alabama USA
30 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Data from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Immune checkpoint inhibition (ICI) constitutes the first-line therapy for relapsed/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) despite low response rates. Some patients treated with ICI experience dissociated response (DR), the coexistence of responding and progression lesions. DR prevalence and prognostic impact in HNSCC are unknown. We retrospectively identified 112 patients treated with ICI at our institution and evaluated their disease characteristics, survival outcomes, and response. Tissue specimens were used to assess the tumor microenvironment (TME). DR occurred in 19% of our patient cohort. DR was more likely in patients with disease involving the cervical lymph nodes [odds ratio (OR), 16.79; P = 0.004]. Patients with DR had a median progression-free and overall survival of 6.7 and 16.9 months, respectively, similar to subjects with partial response (PR) or stable disease (SD). DR was less favorable when it occurred early, and we identified no instances in which early DR converted to uniform objective response. We demonstrated increased CD8+ T-cell infiltration and decreased signal transducer and activator of transcription 3 (STAT3) signaling in tissue from responding versus nonresponding patients. Tumors from patients with DR had low T-cell infiltration and reduced STAT3. In conclusion, DR during ICI therapy in HNSCC is common and associated with favorable prognosis, especially in patients who initially have a complete response (CR) or PR. Early DR as the best response is less beneficial and unlikely to convert to a true response; change in therapy should be considered for these patients. Response patterns may be related to organ-specific differences in the TME. Significance:Mixed response or DR is common in patients with R/M HNSCC who receive immune checkpoint inhibition (ICI). Patients with DR have survival outcomes similar to patients with a PR, especially when DR occurs after an initial uniform response to therapy. DR occurring early in treatment is less favorable and unlikely to convert to uniform response later on.
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Immune checkpoint inhibition (ICI) constitutes the first-line therapy for relapsed/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) despite low response rates. Some patients treated with ICI experience dissociated response (DR), the coexistence of responding and progression lesions. DR prevalence and prognostic impact in HNSCC are unknown. We retrospectively identified 112 patients treated with ICI at our institution and evaluated their disease characteristics, survival outcomes, and response. Tissue specimens were used to assess the tumor microenvironment (TME). DR occurred in 19% of our patient cohort. DR was more likely in patients with disease involving the cervical lymph nodes [odds ratio (OR), 16.79; P = 0.004]. Patients with DR had a median progression-free and overall survival of 6.7 and 16.9 months, respectively, similar to subjects with partial response (PR) or stable disease (SD). DR was less favorable when it occurred early, and we identified no instances in which early DR converted to uniform objective response. We demonstrated increased CD8+ T-cell infiltration and decreased signal transducer and activator of transcription 3 (STAT3) signaling in tissue from responding versus nonresponding patients. Tumors from patients with DR had low T-cell infiltration and reduced STAT3. In conclusion, DR during ICI therapy in HNSCC is common and associated with favorable prognosis, especially in patients who initially have a complete response (CR) or PR. Early DR as the best response is less beneficial and unlikely to convert to a true response; change in therapy should be considered for these patients. Response patterns may be related to organ-specific differences in the TME. Significance:Mixed response or DR is common in patients with R/M HNSCC who receive immune checkpoint inhibition (ICI). Patients with DR have survival outcomes similar to patients with a PR, especially when DR occurs after an initial uniform response to therapy. DR occurring early in treatment is less favorable and unlikely to convert to uniform response later on.
- Open Access
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Patient selection process and DR examples. A, Initial screen identified patients with HNSCC treated with ICI. Patients were excluded if treated outside of the R/M setting, stopped ICI prior to receiving three cycles, or clinical records and/or imaging were incomplete. B, Radiology example of late DR. Patient had a large neck mass on baseline scans. Best response occurred at 6 months on treatment with substantial PR in the neck. Ten months after treatment start, the patient had a late DR with sustained PR in the neck but PD in the axillary lymph nodes which were treated locally with radiation. Overall PD occurred after 14 months on treatment with progression in the neck and diffusely through the lungs. C, Radiology example of early DR. Patient had a pleural-based mass on pretreatment scans. Best response and early DR occurred at 3 months on treatment with PR of the pleural-based lesion but PD in the right hilum. Patient continued on ICI alone and developed overall PD after 4 months on treatment with continued progression of hilar lymph nodes along with increased subcarinal and mediastinal lymphadenopathy.
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Patient selection process and DR examples. A, Initial screen identified patients with HNSCC treated with ICI. Patients were excluded if treated outside of the R/M setting, stopped ICI prior to receiving three cycles, or clinical records and/or imaging were incomplete. B, Radiology example of late DR. Patient had a large neck mass on baseline scans. Best response occurred at 6 months on treatment with substantial PR in the neck. Ten months after treatment start, the patient had a late DR with sustained PR in the neck but PD in the axillary lymph nodes which were treated locally with radiation. Overall PD occurred after 14 months on treatment with progression in the neck and diffusely through the lungs. C, Radiology example of early DR. Patient had a pleural-based mass on pretreatment scans. Best response and early DR occurred at 3 months on treatment with PR of the pleural-based lesion but PD in the right hilum. Patient continued on ICI alone and developed overall PD after 4 months on treatment with continued progression of hilar lymph nodes along with increased subcarinal and mediastinal lymphadenopathy.
- Open Access
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Supplemental Table 1. Clinical characteristics associated with timing of DR.
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Supplemental Table 1. Clinical characteristics associated with timing of DR.
- Open Access
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Organ-specific treatment response rates and impact of overall treatment response on survival outcomes. A, Organ-specific treatment responses for local disease (n = 54), cervical lymphadenopathy (n = 42), lung metastases (n = 59), other (noncervical) lymph nodes (LN; n = 45), and other sites of disease (bone, liver, skin and soft tissue, and/or brain, n = 26). B, Kaplan–Meier estimates of PFS (left) and OS (right) in months. Top, RECIST response classifications. Middle, subdivided response categories demonstrated that DR was similar to SD and PR with respect to clinical outcomes. Bottom, late DR had more favorable impact on survival than early DR. There were 86 PFS events and 61 OS events in the total cohort, and 19 PFS events and 14 OS events in the DR subgroup. Tick marks indicate censored data.
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Organ-specific treatment response rates and impact of overall treatment response on survival outcomes. A, Organ-specific treatment responses for local disease (n = 54), cervical lymphadenopathy (n = 42), lung metastases (n = 59), other (noncervical) lymph nodes (LN; n = 45), and other sites of disease (bone, liver, skin and soft tissue, and/or brain, n = 26). B, Kaplan–Meier estimates of PFS (left) and OS (right) in months. Top, RECIST response classifications. Middle, subdivided response categories demonstrated that DR was similar to SD and PR with respect to clinical outcomes. Bottom, late DR had more favorable impact on survival than early DR. There were 86 PFS events and 61 OS events in the total cohort, and 19 PFS events and 14 OS events in the DR subgroup. Tick marks indicate censored data.
- Open Access
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
TILs are associated with treatment response patterns. A, Quantification and (B) IHC images of CD8+ T cells showed increased infiltration in the parenchyma of responders (R) vs. nonresponders (NR) or dissociated responders. No differences were observed in the stroma. Brown, CD8; red, CD3. C, Early DR cases demonstrated higher CD8+ T-cell invasion compared with late DR cases in both the parenchyma and stroma. Five representative images per case were quantified; lines represent mean, and errors bars represent standard error of the mean. DR, dissociated response.
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
TILs are associated with treatment response patterns. A, Quantification and (B) IHC images of CD8+ T cells showed increased infiltration in the parenchyma of responders (R) vs. nonresponders (NR) or dissociated responders. No differences were observed in the stroma. Brown, CD8; red, CD3. C, Early DR cases demonstrated higher CD8+ T-cell invasion compared with late DR cases in both the parenchyma and stroma. Five representative images per case were quantified; lines represent mean, and errors bars represent standard error of the mean. DR, dissociated response.
- Open Access
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Differential activity of PD-L1 interactome signaling based on tumor response. A, Quantification of PD-L1, ILF3, STAT3, and pSTAT3 showed increased ILF3 and STAT3 expression in nonresponding tumors. NR, nonresponders; R, responders. B, Representative IHC images of ILF3 and STAT3 staining by response type. C, All components of the PD-L1 interactome were increased in early compared with late DR cases. Five representative images per case were quantified; lines represent mean, and errors bars represent standard error of the mean. D, Top, differences in STAT3 expression by treatment response were specific to tissue samples collected just prior to ICI initiation. E, Multicolor PLA representative images (left) and quantification (right) revealed significantly higher PD-L1 intracellular signaling activity in nonresponding vs. responding cases as demonstrated by increased interaction between PD-L1–ILF3 and PD-L1–STAT3. Five cases per group with quantification from five representative images. Scale bars, 10 μm (left); magnified PLA is 4× original size.
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Differential activity of PD-L1 interactome signaling based on tumor response. A, Quantification of PD-L1, ILF3, STAT3, and pSTAT3 showed increased ILF3 and STAT3 expression in nonresponding tumors. NR, nonresponders; R, responders. B, Representative IHC images of ILF3 and STAT3 staining by response type. C, All components of the PD-L1 interactome were increased in early compared with late DR cases. Five representative images per case were quantified; lines represent mean, and errors bars represent standard error of the mean. D, Top, differences in STAT3 expression by treatment response were specific to tissue samples collected just prior to ICI initiation. E, Multicolor PLA representative images (left) and quantification (right) revealed significantly higher PD-L1 intracellular signaling activity in nonresponding vs. responding cases as demonstrated by increased interaction between PD-L1–ILF3 and PD-L1–STAT3. Five cases per group with quantification from five representative images. Scale bars, 10 μm (left); magnified PLA is 4× original size.
- Open Access
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Supplemental Table 2. Response by disease site in patients with DR.
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Supplemental Table 2. Response by disease site in patients with DR.
- Open Access
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Supplemental Figure 1. Timing of treatment responses in patients with DR. Timing of best response (red), dissociated response (DR, orange), and overall progression of disease (PD, blue) in months from the time of first immunotherapy cycle in patients with dissociated response. Those patients where best response and dissociated response occurred at the same time were classified as early DR (grouped at the top), and those patients where dissociated response occurred at least 1 month after best response were classified as late DR (grouped at the bottom).
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Supplemental Figure 1. Timing of treatment responses in patients with DR. Timing of best response (red), dissociated response (DR, orange), and overall progression of disease (PD, blue) in months from the time of first immunotherapy cycle in patients with dissociated response. Those patients where best response and dissociated response occurred at the same time were classified as early DR (grouped at the top), and those patients where dissociated response occurred at least 1 month after best response were classified as late DR (grouped at the bottom).
- Open Access
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Supplemental Figure 2. Survival outcomes based on lung-specific treatment response. Kaplan-Meier estimates of progression free survival (PFS, left) and overall survival (OS, right) in months based on organ-specific treatment response of lung metastases. Tick marks indicate censored data. Abbreviations: complete response (CR), not reached (NR), partial response (PR), stable disease (SD), and progressive disease (PD).
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Supplemental Figure 2. Survival outcomes based on lung-specific treatment response. Kaplan-Meier estimates of progression free survival (PFS, left) and overall survival (OS, right) in months based on organ-specific treatment response of lung metastases. Tick marks indicate censored data. Abbreviations: complete response (CR), not reached (NR), partial response (PR), stable disease (SD), and progressive disease (PD).
- Open Access
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Clinical characteristics associated with treatment response.
- 8 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes
Clinical characteristics associated with treatment response.